Phenotypes and Lung Microbiota Signatures of Immunocompromised Patients with Pneumonia-Related Acute Respiratory Distress Syndrome
Yan Hu,Jiawei Shen,Youzhong An,Yanwen Jiang,Huiying Zhao
DOI: https://doi.org/10.2147/jir.s453123
IF: 4.5
2024-03-02
Journal of Inflammation Research
Abstract:Yan Hu, 1, &ast Jiawei Shen, 2, &ast Youzhong An, 2 Yanwen Jiang, 1 Huiying Zhao 2 1 Department of Respiratory and Critical Care Medicine, Peking University International Hospital, Beijing, People's Republic of China; 2 Department of Critical Care Medicine, Peking University People's Hospital, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Huiying Zhao, Department of Critical Care Medicine, Peking University People's Hospital, Beijing, People's Republic of China, Email Objective: We aim to identify the clinical phenotypes of immunocompromised patients with pneumonia-related ARDS, to investigate the lung microbiota signatures and the outcomes of different phenotypes, and finally, to develop a machine learning classifier for a specified phenotype. Methods: This prospective study included immunocompromised patients with pneumonia-related ARDS. We identified phenotypes using hierarchical clustering to analyze clinical variables and serum cytokine levels. We then compared outcomes and lung microbiota signatures between phenotypes. Based on lung microbiota markers, we developed a random forest classifier for a specified phenotype with worse outcomes. Results: This study included 92 patients, who were divided into three phenotypes, namely "type α" (N = 33), "type β" (N = 12), and "type γ" (N = 47). Compared to type α or type β, patients with type γ had no obvious inflammatory presentation and had significantly lower IL-6 levels and more severe oxygenation failure. Type γ was also related to higher 30-day mortality and lower ventilator free days. The microbiota signatures of type γ were characterized by lower alpha diversity and distinct compositions than those of other patients. We developed a lung microbiota-derived random forest model to differentiate patients with type γ from other phenotypes. Conclusion: Immunocompromised patients with pneumonia-related ARDS can be clustered into three clinical phenotypes, namely type α, type β, and type γ. Phenotypes were distinguished from each other with different outcomes and lung microbiota signatures. Type γ, which was characterized by insufficient inflammation response and worse outcomes, can be detected with a random forest model based on lung microbiota markers. Keywords: immunocompromised host, respiratory failure, microbiota With the progression of oncology and rheumatology, the prognosis of patients with various malignancies or auto-immune diseases has been greatly improved. 1–3 Yet many patients are in an immunocompromised state after chemotherapy or immunosuppressive treatments, and their risk of opportunistic infections increases significantly. 4,5 Life-threatening infectious complications occur frequently, and patients need to be transferred to Intensive Care Units (ICU) for advanced life supports. 6 Acute respiratory distress syndrome (ARDS) is a common complication that accompanies pulmonary infection in immunosuppressed patients. 7,8 Previous studies have shown that, for immunosuppressed patients with ARDS, the ICU mortality rate is 50–75%, which is much higher than for immunocompetent patients. 9,10 On the other hand, there is significant heterogeneity in the results of studies that focused on the evaluation of outcome and treatment methods: the study by Hilbert et, al. suggested that, when compared to traditional oxygen therapy, non-invasive mechanical ventilation can significantly reduce ICU mortality in these patients, 11 while subsequent studies did not reach a consistent conclusion. 12–14 Some studies have suggested that glucocorticoid treatment may improve outcomes in selected patients, 15,16 but this result could not be replicated in immunocompromised hosts 17 or other patients. 18,19 This evidence suggests that novel methods are necessary to predict patient prognosis and their response to specific treatments to ensure appropriate support for specified patients. Recent studies on ARDS patients have shown that latent class analysis or supervised learning like clustering can be used to classify patients into different phenotypes based on their basic clinical variables and their serum cytokine levels. Calfee's research suggests that ARDS patients can be divided into hyperinflammatory (high IL-6, IL-8, TNFr1, etc.) and hypoinflammatory phenotypes. 20 These two phenotypes were characterized by different clinical outcomes and responses to steroids and fluid managements. 21,22 For immunocompromised hosts, no studies investigated whether such phenotypes existed or were clinically relevant. -Abstract Truncated-
immunology